Kimberly Manhard

Ms. Manhard has served as a member of their board of directors since June 2020. She has been a member of the board of directors of Heron Therapeutics Inc. (Heron) since October 2019 and has served as their Executive Vice President, Drug Development since 2016. Ms. Manhard also served as a director of Heron from 2014 to 2016 until she joined the management team. She has more than 25 years of experience in drug development, regulatory affairs, and pharmaceutical operations.

From 2006 to 2016, Ms. Manhard served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences Inc. (Ardea). In her role at Ardea, she was instrumental in the development and 2015 regulatory approval of lesinurad (Zurampic). Before joining Ardea in 2006, she was President of her consultancy firm, Vice President of Regulatory Affairs for Exelixis Inc., and held multiple regulatory positions at Agouron Pharmaceuticals Inc., a division of the Warner-Lambert Company, supporting development and commercialization of anticancer and antiviral products, including nelfinavir (Viracept).

Ms. Manhard was also previously with Bristol-Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including paclitaxel (Taxol) and infectious disease compounds, including didanosine (Videx) and stavudine (Zerit). She began her career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance Inc.). Ms. Manhard is a member of the board of trustees for the Fleet Science Center. She received a B.S. in Zoology and a B.A. in French from the University of Florida.